

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: March 3, 2010

Electronic Signature for Nicholas J. DiCeglie, Jr.: /Nicholas J. DiCeglie, Jr./

Docket No.: 62660(52171)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Alexander Doemling et al.

Application No.: 10/520,791

Confirmation No.: 3248

Filed: January 8, 2005

Art Unit: 1654

For: TUBULYSIN CONJUGATES

Examiner: S. R. Gudibande

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir/Madam:

Applicant has been informed that the Terminal Disclaimer originally filed January 26, 2010, was disapproved by the USPTO for the following reason: *'The person who signed the TD does not have POA, 3.73(b) statement and, thus not attny of record, see FP 14.29.01 and 14.30, also resubmit TD with these papers, no fee is required.'*

To that end, Applicant submits herewith a new Terminal Disclaimer, signed by Wolfgang Richter, CEO of R&D Biopharmaceuticals GmbH, the assignee of the application. A Statement under 3.73(b) and a Power of Attorney authorizing the attorneys who signed the earlier disqualified Terminal Disclaimers are also provided. Applicant previously paid the Terminal Disclaimer fee on

December 15, 2009, and, thus, believes that no additional fees are required for consideration and entry of this paper. However, Applicants authorize the Director to charge any required fee or credit any overpayment to Deposit Account No. 04-1105.

Dated: March 3, 2010

Respectfully submitted,

Electronic signature: /Nicholas J. DiCeglie, Jr./

Nicholas J. DiCeglie, Jr.

Registration No.: 51,615

Edwards Angell Palmer & Dodge LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 239-0100

Attorneys/Agents For Applicant

Customer No. 21874